Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207,440,936
-
Total 13F shares
-
51,686,713
-
Share change
-
-1,536,120
-
Total reported value
-
$240,127,422
-
Put/Call ratio
-
29%
-
Price per share
-
$4.64
-
Number of holders
-
118
-
Value change
-
-$9,961,168
-
Number of buys
-
66
-
Number of sells
-
49
Institutional Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q1 2022
As of 31 Mar 2022,
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) was held by
118 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,686,713 shares.
The largest 10 holders included
WASATCH ADVISORS INC, Deep Track Capital, LP, VANGUARD GROUP INC, Meditor Group Ltd, Bellevue Group AG, BlackRock Inc., PLATINUM INVESTMENT MANAGEMENT LTD, Altium Capital Management LP, MILLENNIUM MANAGEMENT LLC, and Paradigm Biocapital Advisors LP.
This page lists
119
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.